http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2325207-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fac65659bfec1cdbccaa51b16b8b1d59
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2893
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
filingDate 2005-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1039b2538398c980f9fb56d854bf8ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a53351273713c83989130ea306b6554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11bec5f97350f8f5a7fbd2efd974897b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2127aa333652cc62f77ca4105f331b13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39599964f12293099679f35463437d08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70f79e0ace8b898fc9cbac380a368da6
publicationDate 2011-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2325207-A3
titleOfInvention FC variants with altered binding to FCRN
abstract The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. nAn exemplary embodiment is a human IgG Fc polypeptide variant comprising a tryptophan at position 308, wherein said variant exhibits increased binding to FcRn.
priorityDate 2004-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004063351-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9823289-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006104989-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005047327-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398728
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1148

Total number of triples: 38.